Current research advance on cellular immunotherapy for leukemia-review.
10.7534/j.issn.1009-2137.2013.05.048
- Author:
Hong TIAN
1
;
Guang-Hua CHEN
;
Yang XU
;
Man QIAO
;
Hui-Wen LIU
;
De-Pei WU
Author Information
1. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Immunotherapy, Adoptive;
Leukemia;
therapy;
T-Lymphocytes, Cytotoxic;
immunology
- From:
Journal of Experimental Hematology
2013;21(5):1326-1330
- CountryChina
- Language:Chinese
-
Abstract:
Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens (LAA) that are recognized by cytotoxic T cell (CTL) in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer (DC-CIK) cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.
